ArticleEuropean journal of nuclear medicine and molecular imaging2011
Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01981707 (F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- [Molecular imaging and biology · 2025Trial
- Review
- Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.Tomography (Ann Arbor, Mich.) · 2022Article
- Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.Nutrients · 2022Review
- Diagnostic performance ofAmerican journal of nuclear medicine and molecular imaging · 2021Article
- A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis.Diagnostics (Basel, Switzerland) · 2020Article
- The effect of androgen deprivation therapy onEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Biological principles and clinical application of positron emission tomography-tracers in prostate cancer: a review.Prostate international · 2019Review
- The use of PET/CT in prostate cancer.Prostate cancer and prostatic diseases · 2018Review
- Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.Oncotarget · 2018Article
- PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.European journal of nuclear medicine and molecular imaging · 2017Review
- PET Tracers Beyond FDG in Prostate Cancer.Seminars in nuclear medicine · 2016Review
- Article
- Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.Frontiers in oncology · 2016Review
- [Radionuclide therapy and diagnostics in urology].Der Urologe. Ausg. A · 2015Article
- Imaging biomarkers in prostate cancer: role of PET/CT and MRI.European journal of nuclear medicine and molecular imaging · 2015Review
- Article
- Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?European journal of nuclear medicine and molecular imaging · 2014Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe influence of androgen deprivation therapy (ADT) on (11)C-choline uptake in patients with prostate cancer (PC) has not yet been clarified. The aim of our study was to investigate this issue by means of sequential (11)C-choline positron emission tomography (PET)/CT in patients with recurrent PC.
methodsWe retrospectively studied 14 recurrent PC patients (mean age 67 years, range 55-82) during follow-up after radical prostatectomy (RP) with rising serum prostate-specific antigen (PSA) levels. All patients had undergone at least two consecutive (11)C-choline PET/CT scans: the first (11)C-choline PET/CT before commencing ADT and the second (11)C-choline PET/CT after 6 months of ADT administration.
resultsThe mean serum PSA level before ADT was 17.0 ± 44.1 ng/ml. After 6 months of ADT administration the PSA value significantly decreased in comparison to baseline (PSA = 2.4 ± 3.1 ng/ml, p < .025). Moreover, before starting ADT, 13 of 14 patients had positive (11)C-choline PET/CT for metastatic spread, while after 6 months of ADT administration in 9 of 14 patients (11)C-choline PET/CT became negative.
conclusionThese preliminary results suggest that ADT significantly reduces (11)C-choline uptake in androgen-sensitive PC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.